MolDX: Breast Cancer Index (BCI) Gene Expression Test Final LCD - Effective April 16, 2019
The following Local Coverage Determination (LCD) has completed the Open Public and Contractor Advisory Committee (CAC) comment period and is now finalized under contractor numbers 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI) and 01312(NV). Responses to comments received may be found as a link at the bottom of the final LCD.
Medicare Coverage Database (MCD) Number/Contractor Determination Number: L37822
LCD Title: MolDX: Breast Cancer IndexTM (BCI) Gene Expression Test
Effective Date: April 16, 2019
Summary of LCD: This Medicare contractor will provide limited coverage for the Breast Cancer IndexTM (BCI) gene expression test (Biotheranostics, Inc., San Diego, CA) for the management of postmenopausal women diagnosed with early-stage (TNM stage T1-3, pN0, M0), node-negative, non-relapsed, ER and/or PR-positive, HER2-negative breast cancer, who are being or will be treated with primary adjuvant endocrine therapy. The BCI test is used by physicians to provide a genomic-based estimate of 10y distant recurrence risk when considering addition of chemotherapy, and/or late distant recurrence risk and endocrine responsiveness when considering extension of endocrine therapy, depending upon when in the continuum of care testing is requested.
Access Noridian Future Effective LCDs.
- Go to Future LCD webpage
- The End User Agreement for Providers will appear if you have not recently visited the website. Select "Accept" (if necessary)
- Select coordinating state and locate above listed CMS MCD number or LCD title
- This link will redirect you to state specific Future Effective LCD on CMS website
Last Updated Mar 04, 2019